CLOs on the Move

Coeptis Therapeutics

www.coeptistx.com

 
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively "Coeptis"), is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis` product portfolio and rights are highlighted by a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and intellectual property and knowhow related to the GEAR™ cell therapy and companion diagnostic platforms, which Coeptis is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet. Coeptis` business model is designed around maximizing the ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.coeptistx.com
  • 105 Bradford Road Suite 420
    Wexford, PA USA 15090
  • Phone: 724.934.6467

Executives

Name Title Contact Details
Christine Sheehy
Vice President of Compliance and Corporate Secretary Profile

Similar Companies

FFF Enterprises Inc

FFF Enterprises Inc is a Temecula, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Advanced Targeting Systems

Advanced Targeting Systems is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Citizens Rx

Citizens Rx provides pharmacy benefit management services to public and private companies and offers health plans in the United States.

Akcea Therapeutics

Akcea Therapeutics is a development and commercialization company focused on helping patients with serious diseases. Our priority is to drive clinical program execution, understand patient and physician needs, prepare the market, create market access, and commercialize our products on a global basis. We are driven by knowing that patients depend on us. An affiliate of Ionis Pharmaceuticals and based in Kendall Square, Cambridge, Massachusetts, Akcea was founded with a robust portfolio of development-stage drugs covering multiple targets and disease states using advanced antisense therapeutics. Akcea is derived from the Greek word for value and worth. Something that has akcea (αξία) is not common, but precious and rare. Our name supports the value we are creating for physicians, patients and their families, and other key stakeholders as we seek to commercialize a robust portfolio of development-stage, advanced, antisense therapies for serious cardiometabolic lipid disorders. Our immediate focus is to drive our clinical programs forward through development to commercialization while building on the Isis standards of excellence.